Prof. Kris Thielemans, MD, PhD, started his research career in the laboratory of Dr. R. Levy at the department of oncology of the Stanford University Medical School (CA, USA), and returned to his alma mater in Brussels (VUB), in the Laboratory of Molecular and Cellular Therapy (LMCT). In his academic research career, Kris Thielemans focused on immunotherapeutic translational research, including clinical studies for the treatment of cancer and HIV. With this team, he developed the mRNA based TriMix technology and initiated several phase I and II clinical trials in this field.
In 2013, Kris Thielemans founded eTheRNA NV. Under his stewardship, the academic research organisation was transformed into a biotechnology company by bringing different team members on board.